Clinical Trials at
Phoenix 7th

Atopic Dermatitis (Corrona Registry)

Corrona Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness

View Trial

Private: Atopic Dermatitis (Eli Lilly and Company Study)

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.

View Trial

Moderate-to-Severe Atopic Dermatitis Study (12 Years+)

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults Study Description Treatment with nemolizumab will be determined solely by the participant’s physician prior to study enrollment. No additional visits, procedures, or laboratory tests are required outside of routine clinical practice. The visit structure is not defined by the study ...

View Trial

Moderate-to-Severe Atopic Dermatitis Study (12-75 Years)

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis Study Description This study includes a 35-day screening period, a 16-week double-blind period, a blinded extension period up to Week 260, a blinded Long-term Extension (LTE) Period after Week ...

View Trial

Severe Atopic Dermatitis Study (18 Years+)

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of PF-07275315 and PF-07264660 in Adult Participants with Moderate – Severe Atopic Dermatitis Study Description In Stage 1 of the study, participants will receive either PF-07275315 or PF-07264660 or placebo. Stage 1 is complete. In Stage 2 of the study participants will ...

View Trial

Moderate-to-Severe Atopic Dermatitis Study (12 Years+)

An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Participants aged 12 Years and Older with Moderate-to-Severe Atopic Dermatitis Study Description The study duration per participant will be up to 284 weeks, including: A screening period of up to 2 to 4 weeks An open label treatment ...

View Trial

Hidradenitis Suppruativa Study (12 Years+)

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa Study Description   Brief Summary The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. Condition or Disease Hidradenitis Suppruativa Study Design Study Type: Interventional (Clinical Trial) ...

View Trial

Moderate-to-Severe Hidradenitis Suppruativa Study (12 Years+)

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy Study Description This study is “double-blinded”, meaning that neither the trial participants nor the study doctors will know who will be given upadacitinib and who ...

View Trial

Moderate-to-Severe Hidradenitis Suppruativa Study (18-75 Years)

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Moderate to Severe Hidradenitis Suppurativa Study Description This study consists of a 16-week Double-blind Period and a 100-week Long-term Extension (LTE) composed of a 40-week Main Extension and a 60-week Optional Extension.   Brief Summary This is ...

View Trial

Moderate-to-Severe Hidradenitis Suppruativa Study (18-100 Years)

A Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicenter, Phase 3 Study Assessing the Efficacy, Safety, and Tolerability of 2 Doses of Remibrutinib Over a 68-week Treatment Period in Adult Patients With Moderate to Severe Hidradenitis Suppurativa Study Description The total duration of the study is 76 weeks and consists of: Screening (up to 4 weeks), Treatment Period ...

View Trial

Moderate-to-Severe Hidradenitis Suppruativa Study (9-17 Years)

A Multicenter, Open-Label Study to Assess The Pharmacokinetics And Safety of Bimekizumab in Pubertal Children And Adolescents With Moderate to Severe Hidradenitis Suppurativa Study Description   Brief Summary The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS) Condition ...

View Trial

Hidradenitis Suppruativa Study (18-70 Years)

A Phase 2, Multi-Center Study Consisting of a Randomized, Placebo-Controlled Period, Followed by an Open-Label Extension Period to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Hidradenitis Suppurativa Study Description   Brief Summary The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in ...

View Trial

Basal Cell Carcinoma Study (18 Years+)

Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas Study Description Blue light PDT has shown some success in treating BCCs, but more research is needed to evaluate this treatment modality further. The objective of this study is to evaluate the safety and efficacy of using photodynamic Therapy with Sonidegib for the treatment of ...

View Trial

Cutaneous T-Cell Lymphoma (CTCL) Study (18 Years+)

A Confirmatory Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Topical HyBryte™ (Hypericin Sodium) and Visible-Light Activation for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) Study Description The primary objective of this Phase 3 study is to evaluate the ability of an 18-week course of HyBryte and visible light to induce a ...

View Trial

Skin Cancer Research Study (18 Years+)

An Open-Label, Multicenter, Phase 1B/2 Study of RP1 in Solid Organ and Hematopoietic Cell Transplant Recipients With Advanced Cutaneous Malignancies Study Description Patients will participate up to approximately 3 years including a 28-day screening period, up to approximately 1 year treatment period, and a 2-year follow-up period. RP1 is a genetically modified herpes simplex type ...

View Trial

Cutaneous Squamous Cell Carcinoma Study (18 Years+)

A Prospective International Multicenter, Pivotal, Single Arm, Open Label Clinical Study to Assess the Efficacy and Safety of Intratumoral Alpha DaRT224 for the Treatment of Patients with Recurrent Cutaneous Squamous Cell Carcinoma Study Description This study is a prospective multicenter, pivotal, single arm, open label clinical study to assess the efficacy and safety of intratumoral ...

View Trial